Children's FA drug trial opens: could omaveloxolone help younger patients?
NCT ID NCT06054893
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 25 times
Summary
This study tests an approved FA drug (omaveloxolone) in 35 children aged 2 to 15 to see how their bodies process it and whether it is safe. The drug is already available for patients 16 and older. Researchers will monitor side effects, growth, and heart health over up to 240 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRIEDREICH ATAXIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.